Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Evolus Inc EOLS

Healthcare
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar... see more

Recent & Breaking News (NDAQ:EOLS)

Evolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the Year

Business Wire May 10, 2024

Evolus Reports First Quarter 2024 Results and Provides Business Update

Business Wire May 7, 2024

Evolus to Report First Quarter Financial Results on May 7, 2024

Business Wire April 23, 2024

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®

Business Wire April 17, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire April 12, 2024

Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Business Wire March 26, 2024

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

Business Wire March 11, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 8, 2024

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

Business Wire March 7, 2024

Evolus Announces Results from European Head-to-Head Filler Trial

Business Wire March 1, 2024

Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences

Business Wire February 27, 2024

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

Business Wire February 22, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire February 9, 2024

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

Business Wire January 16, 2024

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 12, 2024

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

Business Wire January 4, 2024

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

Business Wire December 20, 2023

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire December 8, 2023

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 10, 2023

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

Business Wire November 7, 2023